{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:59:27Z","timestamp":1786323567358,"version":"build-2736575974"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:00:00Z","timestamp":1546819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.01467","type":"journal-article","created":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T06:09:59Z","timestamp":1546841399000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Risk of Heart Failure Hospitalization Associated With Cilostazol in Diabetes: A Nationwide Case\u2013Crossover Study"],"prefix":"10.3389","volume":"9","author":[{"given":"Cho-Kai","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jou-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Chiu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hsuin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4857","article-title":"Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study.","volume":"354","author":"Arfe","year":"2016","journal-title":"BMJ"},{"key":"B2","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/00005344-199804000-00010","article-title":"Chronotropic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias.","volume":"31","author":"Atarashi","year":"1998","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1056\/NEJM198309293091302","article-title":"Evaluation of a new bipyridine inotropic agent\u2013milrinone\u2013in patients with severe congestive heart failure.","volume":"309","author":"Baim","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12012-008-9019-x","article-title":"Antiplatelet agents sarpogrelate and cilostazol affect experimentally-induced ventricular arrhythmias and mortality.","volume":"8","author":"Barta","year":"2008","journal-title":"Cardiovasc. Toxicol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1056\/NEJM197812212992501","article-title":"Hemodynamic assessment of amrinone. A new inotropic agent.","volume":"299","author":"Benotti","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-015-0114-1","article-title":"Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.","volume":"15","author":"Bundhun","year":"2015","journal-title":"BMC Cardiovasc. Disord."},{"key":"B7","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jfma.2014.05.001","article-title":"Effectiveness and safety of extracranial carotid stent placement: a nationwide self-controlled case-series study.","volume":"114","author":"Chang","year":"2015","journal-title":"J. Formos. Med. Assoc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1161\/STROKEAHA.110.585828","article-title":"Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study.","volume":"41","author":"Chang","year":"2010","journal-title":"Stroke"},{"key":"B9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/00005344-199910000-00004","article-title":"Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells.","volume":"34","author":"Cone","year":"1999","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1161\/01.CIR.98.7.678","article-title":"Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.","volume":"98","author":"Dawson","year":"1998","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1056\/NEJM199307153290301","article-title":"Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone study group.","volume":"329","author":"Feldman","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1172\/JCI111742","article-title":"Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.","volume":"75","author":"Jaski","year":"1985","journal-title":"J. Clin. Invest."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1378\/chest.123.4.1161","article-title":"Effect of cilostazol on the ventricular escape rate and neurohumoral factors in patients with third-degree atrioventricular block.","volume":"123","author":"Kodama-Takahashi","year":"2003","journal-title":"Chest"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.08.017","article-title":"NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease.","volume":"127","author":"Kohli","year":"2014","journal-title":"Am. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.biopha.2017.07.143","article-title":"Cilostazol protects mice against myocardium ischemic\/reperfusion injury by activating a PPAR\u03b3\/JAK2\/STAT3 pathway.","volume":"94","author":"Li","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1527-3466.2001.tb00076.x","article-title":"Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.","volume":"19","author":"Liu","year":"2001","journal-title":"Cardiovasc. Drug Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1139\/y94-199","article-title":"Cyclic nucleotide dependent relaxation in vascular smooth muscle.","volume":"72","author":"McDaniel","year":"1994","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1071-9164(03)00135-0","article-title":"PDE3 inhibition in dilated cardiomyopathy: reasons to reconsider.","volume":"9","author":"Movsesian","year":"2003","journal-title":"J. Card. Fail."},{"key":"B19","doi-asserted-by":"publisher","first-page":"35A","DOI":"10.1016\/0002-9149(89)90391-3","article-title":"Electrophysiology of phosphodiesterase inhibitors.","volume":"63","author":"Naccarelli","year":"1989","journal-title":"Am. J. Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.jacc.2013.11.027","article-title":"Resting heart rate as predictor for left ventricular dysfunction and heart failure: MESA (multi-ethnic study of atherosclerosis).","volume":"63","author":"Opdahl","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure. The promise study research group.","volume":"325","author":"Packer","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0006-2952(94)90062-0","article-title":"Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells.","volume":"48","author":"Pan","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ijcard.2005.11.106","article-title":"Roles of cardiac ryanodine receptor in heart failure and sudden cardiac death.","volume":"112","author":"Phrommintikul","year":"2006","journal-title":"Int. J. Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/clc.4960140506","article-title":"Hemodynamic and neuroendocrine response to acute administration of the phosphodiesterase inhibitor BM14.478 in patients with congestive heart failure.","volume":"14","author":"Rauch","year":"1991","journal-title":"Clin. Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40265-015-0364-3","article-title":"Clinical efficacy and safety of cilostazol: a critical review of the literature.","volume":"75","author":"Rogers","year":"2015","journal-title":"Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1046\/j.1463-1326.2002.0040s2s14.x","article-title":"The pharmacology of cilostazol.","author":"Schror","year":"2002","journal-title":"Diabetes Obes. Metab."},{"key":"B27","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S1474-4422(10)70198-8","article-title":"Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial.","volume":"9","author":"Shinohara","year":"2010","journal-title":"Lancet Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1010-7940(00)00413-9","article-title":"Myocardial efficiency in stunned myocardium. Comparison of Ca(2+)-sensitization and PDE III-inhibition on energy consumption.","volume":"18","author":"Sunderdiek","year":"2000","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"B29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/00005344-200111000-00014","article-title":"Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication.","volume":"38","author":"Wang","year":"2001","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.jacc.2010.04.069","article-title":"Cystatin C and long-term mortality among subjects with normal creatinine-based estimated glomerular filtration rates: NHANES III (third national health and nutrition examination survey).","volume":"56","author":"Wu","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/joim.12262","article-title":"Statin use reduces the risk of dementia in elderly patients: a nationwide data survey and propensity analysis.","volume":"277","author":"Wu","year":"2015","journal-title":"J. Intern. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01467\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T06:10:01Z","timestamp":1546841401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01467\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,7]]},"references-count":31,"alternative-id":["10.3389\/fphar.2018.01467"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.01467","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,7]]},"article-number":"1467"}}